Scam invitations to non-existent conferences
#85547 by StevanHarnad Sun Feb 12, 2012 3:19 am
BIT’s 5th Annual World Congress of Cancer 2012
Theme: Hand-in-Hand for Caring
Time: May 18-20, 2012
Venue: Beijing, China

Dear Dr. [yourname here]

I'm writing to follow-up my last invitation as below, would you please give me a tentative reply? Thank you very much.

I apologize for the inconvenience if the letter disturbed you more than once. On behalf of the Meeting Organizing Committee, it is my pleasure and privilege to invite you to give a speech at BIT’s 5th Annual World Congress of Cancer 2012 with a theme of Hand-in-Hand for Caring.

BIT Congress is proud to launch the 5th Anniversary of World Cancer Congress (WCC), which will be held from May 18 to May 20, 2012 in Beijing, China.

We sincerely invite you to give a speech at the BIT Life Sciences' 5th World Cancer Congress (WCC-2012) by submitting your speech title and CV to us, sharing your expertise in practical knowledge and latest technology, and/or being an active participant. This Conference will continue the resounding success of the past conferences in Beijing and will provide a groundbreaking scientific program will draw together many cancer specialists from a wide range of disciplines from all over the world.

Thanks for assistance from speakers and attendees in WCC2012 in Beijing, China, we have confirmed partial renowned speakers below:
Dr. Paul A Marks, Professor, President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center, USA
Dr. Donald L. Trump, President and Chief Executive Officer, Roswell Park Cancer Institute, USA
Dr. John B. Lowe, Professor, Head, School of Health and Sport Sciences, University of Iowa, USA
Dr. David E Elder, Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, USA
Dr. Michael Andreeff, Professor, the University of Texas MD Anderson Cancer Center, USA
Dr. Brad Thompson, President and CEO, Oncolytics Biotech Inc., Canada
Dr. Peter P. Chou, Director of Scientific Affair, Quest Diagnostics Nichols Institute, USA
Dr. Jonathan Lewis, Chief Executive Officer and Executive Chairman, ZIOPHARM Oncology, USA

Through this international congress it hopes to build upon and develop the great successes already achieved over the past few years. The congress theme of this year is "Hand-in-Hand for Caring" in keeping with the rapid growth and results in cancer research and care throughout the world. The 3-day diverse program has been designed to cover the breadth of oncology from cancer epidemiology and prevention, from drug discovery to cancer treatment and palliative care. It will also cover the main oncological aspects of these themes from molecular biology and genetics, to targeted therapies, innovation technology radiotherapy and imaging.

The program is a very interesting mix of plenary lectures, the technical sessions, educational training courses, practical clinical case as well as industry supported symposia will provide delegates with information on the latest developments in basic science and clinical treatment. Several workshops and posters / papers session will be held concurrently to allow sharing of the excellent experience. The high profile speakers will provide productive form to greatly refresh the participant's knowledge and experience. Participants will enhance practical knowledge for everyday use and explore the most up-to-date information regarding the treatment of cancer.

Please seize this wonderful opportunity and feel free to participate actively in all areas of the conference, I feel confident that you will enjoy both of the scientific program and the fine, traditional city of Beijing.

To facilitate us to know your further interest, we appreciate your advices on:

1. Focused session and speech titles.
2. What’s your opinion to be the session chair/moderator?

Further info about the program, please visit is available at ... rogram.asp

Sincerely yours,

Ms. Nancy Shao
Organizing Committee of World Cancer Congress-2012
East Area, F11, Building 1,
Dalian Ascendas IT Park,
1 Hui Xian Yuan,
Dalian Hi-tech Industrial Zone,
LN 116025, China
Tel: 0086-411-84799609-822
Fax: 0086-411-84799629
Email: [email protected]

Track 1: Breaking Cancer Research and Technology Innovations
Section 1-1: Cancer Pathophysiology
CP110: Mechanism of Metastasis and Invasion
CP111: Formation of the Primary Tumor
CP112: Progressive Growth and Angiogenesis
CP113: Oncologic Emergencies
CP114: Environmental Carcinogens
CP115: Identification of Oncogenes and Cancers

Section 1-2: Cancer Biomarkers
CB120: Emerging Technologies for Cancer Biomarker Discovery and Assay DNA Microarray
CB121: Genomic, Proteomic and Transcriptomic-based Biomarkers in Cancer
CB122: Biomarkers for the Treatment and Progression of Cancers
CB123: Biomarkers for the Prognosis of Cancers
CB124: Methodologies and Applications of Cancer Biomarkers

Section 1-3: Insight into Human Cancers
MC1300: Cancer System Biology
MC1301: Tumor Genetics and Cancer Epigenetics
MC1302: Cancer Genomics, Genomic Instability, and Genome Surveillance
MC1303: Cancer DNA Damage, DNA Repair, and Mitosis
MC1304: Oncogenes, Tumor Suppressors, p53 and Regulation
MC1305: Novel Pathways and Regulations of Cancers
MC1306: Cancer/Tumor Adhesion, Migration, Invasion and Metastasis
MC1307: Tumor Angiogenesis
MC1308: Chromatin Regulation, Telomerase and Cancers
MC1309: Interactions between Host and Tumor
MC1310: Mitochondria and Cancer
MC1311: Cancer Cell Cycle and Check Points
MC1312: Tumor Microenvironment Interactions
MC1313: Cancer Immunomodulation
MC1314: Killing the Tumor Cell
MC1315: Mechanisms of Drug Resistance and Tumor Microenvironment
MC1316: Tumor Immunology and Immunotherapy
MC1317: Molecular Pathology and Toxicology of Cancer

Section 1-4: Circulating Tumor Cells
CTC140: Emerging Technologies for CTC-based Cancer Detection
CTC141: Biological and Molecular Characterization of CTCs
CTC142: Molecular Signatures of CTCs
CTC143: CTCs for Cancer Diagnosis, Prognosis and Treatment
CTC144: Clinical Implications of CTCs Analysis on CTC-Tumor Relationship

Section 1-5: Cancer Stem Cells
CSC150: Molecular Biology of Cancer Stem Cells and Clinical Interrelationships
CSC151: The Cancer Stem Cell Niche
CSC152: Reprogramming and Plasticity of Cancer Stem Cells (CSCs)
CSC153: Cancer Stem Cells Signaling Pathways and Implications
CSC154: Breaking Research on Different Cancer Stem Cells

Section 1-6: Metabolism and Cancer
MC160: Studying Metabolism in Model Organism
MC161: Stress Response and Metabolism Involved in Cancer
MC162: Metabolic Influence of Epigenetics on Cancer
MC163: Metabolism and Programmed Cell Death
MC164: Metabolism, ER and Mitochondria

Section 1-7: Innovative Technologies in Cancer Research
IT170: Protein Chips, Tissue Chips, Lab-On-Chip and Microfluidic
IT171: Cancer Bioinformatics and Informatics
IT172: Animal Models and Mathematical Models
IT173: Nanotechnology in Cancer Research

Section 1-8: Translational Oncology
TO180: Tumor Biomarkers in Clinical Trials
TO181: Personalized Medicine for Cancers
TO182: Developing Rational Strategies for Combination Therapy
TO183: Novel Clinical Trial Design and Companion Diagnostics

Track 2: Tobacco Control and Cancers
TC200: Science, Policy and Public Health on Tobacco Control
TC201: The Growing Tobacco Epidemic, Cancer Risks and Prevention
TC202: Tobacco Carcinogenesis, Pharmacology, Mechanisms and Biomarkers
TC203: Tobacco and Lung Cancer
TC204: Tobacco Control Products and Treatment

Track 3: Anticancer Drug Discovery
-The Search for More Smart Drugs
AD300: New Targets, New Technologies for Anticancer Therapeutics
AD301: Drug Design and Lead Optimization
AD302: High Throughput Screening: Targets, Assays, and Libraries
AD303: Biomarker in Anticancer Drug Discovery
AD304: Pharmacology, ADMET and Anticancer Drug Discover
AD305: Targeting Angiogenesis
AD306: Targeting Cancer Stem Cell Pathway
AD307: Targeting Cell Cycle and Checkpoints
AD308: Targeting DNA Damage Response, DNA Repair, Mitosis and Apoptosis
AD309: Targeting Cancer Epigenetics and The Epigenome
AD310: Targeting Nuclear Serine-Threonine Kinases
AD311: Targeting PI3-Akt-mTOR Pathway and Other Protein Kinases
AD312: Targeting Signaling Pathways and Signal Transduction
AD313: Targeting Ubiquitin-related Pathway
AD314: Targeting Tumor Necrosis Factor (TNF) and Chemokine Receptors
AD315: Targeting Apoptotic Pathways for Novel Therapies in Cancer
AD316: Targeting Wnt Signaling and Hedgehog Signaling Pathways
AD317: Abl and bcr-abl Inhibition
AD318: Telomerase Inhibition
AD319: Inhibition of c-KIT
AD320: Inhibition of Platelet-Derived Growth Factor Receptor (PDGFR) and VEGF
AD321: Next Generation Proteasome Inhibitors
AD322: Anticancer Monoclonal Antibody Discovery
AD323: Anticancer Vaccine and Novel Adjuvant Approaches
AD324: Gene Therapy, and RNAi based Anticancer Drug Discovery
AD325: Anticancer Drug Discovery by Inhibition of Stem Cell Signaling
AD326: Design New Molecules to Surpass Anticancer Drug Resistance
AD327: Aurora Kinases and Their Inhibitors
AD328: BRAF Targeted Therapy of Melanoma
AD329: Targeting Cell Surface Proteins/Apoptosis
AD330: Targeting Tumor Stroma Interaction
AD331: T-Cell Therapies for Cancers
AD332: Targeted Hormonal Therapies
AD333: Targeting Tumor Metabolism
AD334: Novel Cancer Drug Delivery Systems
AD335: Update on Clinical Trials on Anticancer Therapeutics

Track 4: Clinical Oncology and Medical Practice
Section 4-1: Diagnosis and Prognosis of Cancers
DP410: Imaging to Detect Recurrent Cancer
DP411: Blood tests, Cancer Biomarkers for Molecular Diagnosis
DP412: Proteomic Profiling for Cancer Diagnosis
DP413: Real-time PCR and Amplification of Other Technologies
DP414: Imaging and Diagnosis: X-Rays, MRI and MRCP, CT Scanning, PET and Ultrasound

Section 4-2: Clinical Research on Cancers
CT4200: Practical Cancer Chemotherapy
CT4201: Radiotherapy and Medical Device Therapy for Cancer
CT4202: Hormone Therapy in Cancer
CT4203: Cancer Surgery, and Symptom Management
CT4204: Robotics and Tumor Mini-invasive Therapy
CT4205: Botanical Medicine for Cancers in Clinical Practice
CT4206: Integrative Medicine and Interventional Methods in Oncology
CT4207: Clinical Development of Epidermal Growth Factor Receptor (EGFR)
CT4208: Tyrosine Kinase Inhibitors: What Lessons Have We Learned?

Section 4-3: Case Analysis on Diversified Cancers/Solid Tumors
CR4300: Lung and Mediastinum Cancers
CR4301: Breast Cancer
CR4302: Esophageal/Stomach Cancer
CR4303: Prostate Cancer
CR4304: Colorectal Cancer, Colon, Rectal and Anal Cancer Management
CR4305: Melanoma and Non-melanoma Skin Cancers
CR4306: Kidney Cancer, Renal Cell Cancer and Adrenal Cancers
CR4307: Head and Neck Cancers: Nasopharyngeal, Oral Cavity Cancers
CR4308: Hematologic Malignancies
CR4309: Bone, Sarcoma Cancers and Soft Tissue Cancers
CR4310: Overian, Cervical, Vulva, Vagina, Uterine Malignancies and Endometrial Cancers
CR4311: Neuroendocrine, CNS Tumors and Glioblastoma
CR4312: Liver cancer

Section 4-4: Cancer Nursing and Support Care
CN440: Oncology Nursing and Clinical Pain Management
CN441: Palliative Care and Psycho-Oncology
CN442: Quality of Life in Long-term Cancer Survivors
CN443: Cancer Survivorship Research

Track 5: Cancer Prevention, Epidemiology, and Public Health
CP500: Cancer Genetics, Epidemiology, Biostatistics and Prevention
CP501: Cancer Screening, Monitoring, and Counseling for High-Risk Populations
CP502: Food Carcinogen and Safety Control in Public Health
CP503: Cancer Rehabilitation, Nutrition and Complementary Therapy
CP504: Environment and Cancer

If it is not of interest to you, please disregard and we apologize for any inconvenience this may have caused. To prevent further emails, go to

Who is online

Users browsing this forum: No registered users and 2 guests